Renalytix Is An In Vitro Diagnostics Company Founded In 2018Dedicated To Eradicating Kidney Disease Through Innovative Diagnostic Solutionsheadquartered In The United States And Listed On The Aim Market Of The London Stock Exchangerenalytix Develops Artificial Intelligence Enabled Clinical Diagnostic Tools Specifically For Managing Kidney Diseasesthe Company S Flagship Productkidneyintelxis Designed For Patients With Type 2 Diabetesthis Test Provides An Accurate Assessment Of The Likelihood Of Progression Toward Renal Failure And Offers A Simple Kidney Health Risk Scoreaiding Patients And Physicians In Determining Appropriate Treatment Optionsrenalytix Collaborates With Major Healthcare Systemsincluding A Notable Partnership With Icahn Mount Sinai For The Launch Of Kidneyintelxthe Company Is Focused On Expanding Its Reach And Securing Funding To Enhance Its Innovative Diagnostic Solutions
